San Francisco startup Composition Therapeutics can be focusing on an oral, once-every day GLP-one drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June when a mid-phase review confirmed average weight loss of close to six% and it designs to begin An additional mid-stage demo towards the top of this year—that founder and